## Tassilo Volz

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8675043/publications.pdf

Version: 2024-02-01

47 papers

4,816 citations

30 h-index 243625 44 g-index

48 all docs

48 docs citations

times ranked

48

4496 citing authors

#	Article	IF	Citations
1	Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo. Gut, 2022, 71, 372-381.	12.1	40
2	Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and cccDNA silencing in vivo without affecting posttranslational modifications of cccDNA-bound histones. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
3	Murine hepatocytes do not support persistence of Hepatitis D virus monoâ€infection in vivo. Liver International, 2021, 41, 410-419.	3.9	7
4	Strong Replication Interference Between Hepatitis Delta Viruses in Human Liver Chimeric Mice. Frontiers in Microbiology, 2021, 12, 671466.	3.5	5
5	Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system. JHEP Reports, 2021, 3, 100356.	4.9	10
6	Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. Cell Reports Medicine, 2020, 1, 100060.	6.5	18
7	FRI-134-Comparative analysis of intrahepatic and peripheral chemokine responses in chronic hepatitis B, C and D in vivo. Journal of Hepatology, 2019, 70, e446.	3.7	O
8	PS-155-HBV entry inhibition after interferon alpha treatment hinders HBV rebound in hepatocytes that became negative for all HBV markers during interferon treatment. Journal of Hepatology, 2019, 70, e98.	3.7	4
9	Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. Gut, 2019, 68, 150-157.	12.1	65
10	T cell receptor grafting allows virological control of hepatitis B virus infection. Journal of Clinical Investigation, 2019, 129, 2932-2945.	8.2	51
11	A humanized mouse model of liver fibrosis following expansion of transplanted hepatic stellate cells. Laboratory Investigation, 2018, 98, 525-536.	3.7	13
12	Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut, 2018, 67, 542-552.	12.1	125
13	A novel orally available small molecule that inhibits hepatitis B virus expression. Journal of Hepatology, 2018, 68, 412-420.	3.7	109
14	Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. Gastroenterology, 2018, 154, 652-662.e8.	1.3	82
15	Haem oxygenase†polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice. Liver International, 2017, 37, 1128-1137.	3.9	8
16	Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice. Scientific Reports, 2017, 7, 3757.	3.3	47
17	Serum HBV pgRNA as a clinical marker for cccDNA activity. Journal of Hepatology, 2017, 66, 460-462.	3.7	133
18	Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. Journal of Clinical Investigation, 2017, 127, 3177-3188.	8.2	93

#	Article	IF	Citations
19	Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model. Oncotarget, 2017, 8, 115582-115595.	1.8	7
20	Primary Human Hepatocytes Repopulate Livers of Mice Afterln VitroCulturing and Lentiviral-Mediated Gene Transfer. Tissue Engineering - Part A, 2016, 22, 742-753.	3.1	9
21	A Slow Maturation Process Renders Hepatitis B Virus Infectious. Cell Host and Microbe, 2016, 20, 25-35.	11.0	50
22	Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. Journal of Hepatology, 2016, 64, 1033-1040.	3.7	106
23	Experimental Models: Cell Culture and Animal Models. Molecular and Translational Medicine, 2016, , 35-62.	0.4	0
24	Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nature Biotechnology, 2015, 33, 549-554.	17.5	129
25	Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. Journal of Hepatology, 2015, 63, 346-353.	3.7	104
26	Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin. PLoS ONE, 2014, 9, e96533.	2.5	17
27	Multiplexing clonality: combining RGB marking and genetic barcoding. Nucleic Acids Research, 2014, 42, e56-e56.	14.5	49
28	Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology, 2014, 60, 1483-1493.	7.3	120
29	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science, 2014, 343, 1221-1228.	12.6	774
30	Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. Journal of Hepatology, 2014, 60, 538-544.	3.7	74
31	Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. Journal of Hepatology, 2014, 60, 500-507.	3.7	68
32	The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Journal of Hepatology, 2013, 58, 861-867.	3.7	286
33	Strong Antiviral Activity of the New L-Hydroxycytidine Derivative, <scp>L</scp> -HYD4FC, In HBV-Infected Human Chimeric UPA/SCID Mice. Antiviral Therapy, 2012, 17, 623-631.	1.0	10
34	Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncology Reports, 2012, 28, 1077-1083.	2.6	34
35	Primary Human Hepatocytes from Metabolic-Disordered Children Recreate Highly Differentiated Liver-Tissue-Like Spheroids on Alginate Scaffolds. Tissue Engineering - Part A, 2012, 18, 1443-1453.	3.1	15
36	Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology, 2012, 55, 685-694.	7.3	190

#	Article	IF	CITATIONS
37	IFN- $\hat{l}\pm$ inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. Journal of Clinical Investigation, 2012, 122, 529-537.	8.2	492
38	Hepatitis B Virus Limits Response of Human Hepatocytes to Interferon- $\hat{l}_{\pm}$ in Chimeric Mice. Gastroenterology, 2011, 140, 2074-2083.e2.	1.3	137
39	RGB marking facilitates multicolor clonal cell tracking. Nature Medicine, 2011, 17, 504-509.	30.7	134
40	In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology, 2010, 52, 16-24.	7.3	76
41	Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology, 2008, 48, 1079-1086.	7.3	56
42	Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnology, 2008, 26, 335-341.	17.5	369
43	Sequential Combination Therapy Leads to Biochemical and Histological Improvement Despite Low Ongoing Intrahepatic Hepatitis B virus Replication. Antiviral Therapy, 2008, 13, 57-66.	1.0	59
44	Impaired Intrahepatic Hepatitis B Virus Productivity Contributes to Low Viremia in Most HBeAg-Negative Patients. Gastroenterology, 2007, 133, 843-852.	1.3	178
45	Modeling infection with hepatitis B virusesin vivo. Future Virology, 2006, 1, 461-469.	1.8	0
46	Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 2006, 44, 675-684.	7.3	403
47	Small Animal Model Systems for Studying Hepatitis B Virus Replication and Pathogenesis. Seminars in Liver Disease, 2006, 26, 181-191.	3.6	44